- Home
- Equipment
- switzerland
- tumor specificity
Refine by
Tumor Specificity Equipment Supplied In Switzerland
5 equipment items found
Manufactured by:MV BioTherapeutics SA based inBellinzona, SWITZERLAND
MV010/MV004, in cancer immunotherapy • Significant increase of tumor specific cytotoxic T cells infiltrating the tumor microenvironment by combining MV010/MV004 to anti-PD-L1 administration in murine models. • Significantly improved tumor eradication and resistance to subsequent grafting and improved survival in murine models. ...
Manufactured by:Nuclidium AG based inBasel, SWITZERLAND
Nuclidium AG leverages the unique properties of copper radionuclides to advance precision radiotherapy and diagnostics. Their proprietary CuTrace™ platform combines copper nuclides with tumor-specific molecules, creating diagnostic and therapeutic pairs designed to optimize the safety and efficacy profile in cancer treatment. These radionuclides, including ...
by:T3 Pharmaceuticals AG based inBasel, SWITZERLAND
T3 Pharma has developed a proprietary cancer therapy platform based on regulating and harnessing the natural behaviours of live bacteria. The genetically engineered bacteria selectively target solid tumors, where they deliver chosen protein payloads into the ...
Manufactured by:Elthera AG based inSchlieren, SWITZERLAND
L1 cell adhesion molecule (L1CAM) is a cell surface protein which is aberrantly expressed in many different tumor types including pancreatic, ovarian, breast, lung, and colorectal cancer. L1CAM expression increases the malignancy of these tumors by promoting cellular proliferation, metastatic spread, tumor angiogenesis, and resistance to chemotherapy. Accordingly, L1CAM-positive tumors ...
by:CDR-Life based inSchlieren, SWITZERLAND
CDR-Life’s T cell engaging antibodies are potentially transformative in the field of cancer immunotherapies» Prof. Markus G. Manz, MD, Head of Medical Oncology and Hematology at University Hospital and University of Zurich, Switzerland. CDR-Life’s pipeline is based on it’s unique antibody fragment platform. It includes a series of highly cancer-targeted and drug-based ...